Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

BACKGROUND: A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and provided therapeutic benefit lasting 6 months in patients with ALS but did not demonstrate long-term efficacy. This phase III clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Jae-Yong, Lee, Tae Yong, Kim, Kwijoo, Chun, Sehwan, Kim, Min Sung, Shin, Jin-Hong, Sung, Jung-Joon, Kim, Byoung Joon, Kim, Byung-Jo, Oh, Ki-Wook, Kim, Kyung Suk, Kim, Seung Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115933/
https://www.ncbi.nlm.nih.gov/pubmed/35585556
http://dx.doi.org/10.1186/s13063-022-06327-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115933/
https://www.ncbi.nlm.nih.gov/pubmed/35585556
http://dx.doi.org/10.1186/s13063-022-06327-4

Ejemplares similares